Evidence map›Paper›PMID 40809148›Full record

ArticleFrontiers in systems biology2024

Accessible Type 2 diabetes medication through stable expression of Exendin-4 in

Gia Balius, Kiana Imani, Zoë Petroff, Elizabeth Beer, Thiago Brasileiro Feitosa, Nathan Mccall, Lauren Paule, Neo Yixuan Peng, Joanne Shen, Vidhata Singh and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in systems biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gia Balius *Department of Molecular, Cellular and Developmental Biology, University of California, Santa Cruz, CA, United States.
Kiana Imani *Department of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Zoë Petroff *Department of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Elizabeth BeerDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Thiago Brasileiro FeitosaDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Nathan MccallDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Lauren PauleDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Neo Yixuan PengDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Joanne ShenDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Vidhata SinghDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Cambell StrandDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
Jonathan ZauDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.
D L BernickDepartment of Biomolecular Engineering and Bioinformatics, University of California, Santa Cruz, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus affects roughly one in ten people globally and is the world's ninth leading cause of death. However, a significant portion of chronic complications that contribute to mortality can be prevented with proper treatment and medication. Glucagon-like peptide 1 receptor agonists, such as Exendin-4, are one of the leading classes of Type 2 diabetes treatments but are prohibitively expensive. In this study, experimental models for recombinant Exendin-4 protein production were designed in both

Indexed as

Escherichia coliExendin-4MedicationSaccharomyces cerevisiaesynthetic biologyTherapeuticsType 2 diabetes

Identifiers

PMID40809148
PMCPMC12342014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.